Gottlieb Resigns from FDA
ePT--the Electronic Newsletter of Pharmaceutical Technology
Dec. 11, 2006 (Rockville, MD)-Effective Jan. 16, 2007, Scott Gottlieb, MD, deputy commissioner for medical and scientific affairs at the US Food and Drug Administration, will leave the agency and will return to the American Enterprise Institute.
Gottlieb Resigns from FDA
Rockville, MD (Dec. 11)-Effective Jan. 16, 2007, Scott Gottlieb, MD, deputy commissioner for medical and scientific affairs at the US Food and Drug Administration (www.fda.gov), will leave the agency and return to the American Enterprise Institute (AEI, Washington, DC, www.aei.org). Before coming to FDA in July 2005, Gottlieb was a resident fellow at AEI.
During his time at FDA, Gottlieb worked on several policy initiatives such as improving the advisory-committee process and communicating risk information to the public more effectively. In addition, Gottlieb helped to implement new regulations and policies such as the new drug and biologic products labeling rule.
This announcement was made shortly after the US Senate confimed Andrew von Eschenbach as the new FDA commissioner (see "Von Eschenbach Confirmed as FDA Commissioner").
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
